2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1271

Plasma Concentration of S100A8/A9 Proteins Is an Independent Biomarker for Radiological Progression in in Early Rheumatoid Arthritis
Abstract Number: 2578

Plasma Levels of Bone Morphogenetic Protein (BMP) Subgroups and Their Inhibitors (noggin, sclerostin) in Rheumatoid Arthritis Patients and Correlation with Disease Activity, Clinical and Radiographic Progression
Abstract Number: 2718

Plasma Levels of the M2 Macrophage Markers, CD163 and CD206, Changes Reversely and Soluble CD163 Is Associated with Disease Activity in Spondyloarthritis
Abstract Number: 1655

Plasma microRNA Expression Profiles in Ankylosing Spondylitis Patients
Abstract Number: 2092

Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Is Elevated in Patients with Thrombotic Primary Antiphospholipid Syndrome.
Abstract Number: 1009

Plasmacytoid Dendritic Cells Are Activated in Systemic Sclerosis and Contribute to the Disease By Inducing Ifnα and CXCL4
Abstract Number: 905

Platelet Activation, As Measured By Plasma Soluble Glycoprotein VI, Is Not Associated with Disease Activity or Ischaemic Events in Giant Cell Arteritis
Abstract Number: 2065

Platelet FcγRIIa Polymorphism H131R Associates with Subclinical Atherosclerosis and Increased Platelet Activity in SLE
Abstract Number: 2276

Pleiotropic Effect of ABCG2 in Gout
Abstract Number: 1002

Pneumocystis Jiroveci in Rheumatic Disease: A 20 Year Single-Center Experience
Abstract Number: 1177

Pneumocystis Jirovecii Pneumonia in Systemic Autoimmune Inflammatory Diseases
Abstract Number: 67

Polymorphisms of ERAP1, IL23R and TRAILR1 Are Associated with MRI-Sacroiliitis in Early Axial Spondyloarthritis: Data from the French DESIR Cohort
Abstract Number: 882

Polymyalgia Rheumatica Activity Score without C-Reactive Protein
Abstract Number: 1605

Pooled Safety and Efficacy of Sarilumab in Rheumatoid Arthritis Patients 65 Years of Age and Older
Abstract Number: 1767

Poor Body Image in Lupus: Is It Disease Activity, Damage, Sleep, Pain, Fatigue, Stress, Function, Medications, Depression or Fibromyalgia?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].